Hilda Hernandez-Barry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hilda Hernandez-Barry has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dhaya Seshasayee
Department of Antibody Engineering, Genentech, South San Francisco, CA, USA
1 shared publication - Erick R. Castellanos
Department of Structural Biology, Genentech, South San Francisco, CA 94080, USA
1 shared publication - Gerald Nakamura
Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA
1 shared publication - Homer Pantua
BioAssets Corporation, City of Santo Tomas 4234, Batangas, Philippines
1 shared publication - Jian Payandeh
Department of Structural Biology, Genentech Inc., South San Francisco, USA
1 shared publication - Kellen Schneider
Department of Antibody Engineering, Genentech, Inc., South San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
- 29 June 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (3) , e0020221
Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
Antibiotic treatment of life-threatening P. aeruginosa infections is associated with low clinical success, despite the availability of antibiotics that are active in standard microbiological in vitro assays, affirming the need for new therapeutic approaches. Antibiotics often fail in the preclinical stage due to insufficient efficacy against P. aeruginosa .
- 29 June 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (3) , e0020221
Open AccessPotent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
Antibiotic treatment of life-threatening P. aeruginosa infections is associated with low clinical success, despite the availability of antibiotics that are active in standard microbiological in vitro assays, affirming the need for new therapeutic approaches. Antibiotics often fail in the preclinical stage due to insufficient efficacy against P. aeruginosa .